trijardy xr
Generic: empagliflozin, linagliptin, metformin hydrochloride
Labeler: boehringer ingelheim pharmaceuticals, inc.Drug Facts
Product Profile
Brand Name
trijardy xr
Generic Name
empagliflozin, linagliptin, metformin hydrochloride
Labeler
boehringer ingelheim pharmaceuticals, inc.
Dosage Form
TABLET, EXTENDED RELEASE
Routes
Active Ingredients
empagliflozin 25 mg/1, linagliptin 5 mg/1, metformin hydrochloride 1000 mg/1
Manufacturer
Identifiers & Regulatory
Product NDC
0597-0390
Product ID
0597-0390_ca86ce8b-9c04-47d8-94e3-ae041f251fab
Product Type
HUMAN PRESCRIPTION DRUG
Marketing Category
NDA
Application Number
NDA212614
Listing Expiration
2027-12-31
Marketing Start
2020-04-23
Pharmacologic Class
Established (EPC)
Mechanism of Action
Normalized Code Variants
Searchable formats for this product NDC code
Digits Only
05970390
Hyphenated Format
0597-0390
Supplemental Identifiers
RxCUI
UNII
NUI
Packaging Origin
Original Packager
Resolved Product View
Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.
Resolved Identity
Brand Name
trijardy xr (source: ndc)
Generic Name
empagliflozin, linagliptin, metformin hydrochloride (source: ndc)
Application Number
NDA212614 (source: ndc)
Routes
source: ndc
Resolved Composition
Strengths
- 25 mg/1
- 5 mg/1
- 1000 mg/1
Packaging
- 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0390-13)
- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0390-71)
Packages (2)
Ingredients (3)
Linked Drug Pages (1)
Raw FDA Data
View complete raw FDA NDC JSON payload
{"route": ["ORAL"], "spl_id": "ca86ce8b-9c04-47d8-94e3-ae041f251fab", "openfda": {"nui": ["N0000187059", "N0000187058", "N0000175912", "N0000175913"], "unii": ["HDC1R2M35U", "3X29ZEJ4R2", "786Z46389E"], "rxcui": ["2359279", "2359285", "2359288", "2359290", "2359351", "2359353", "2359356", "2359358"], "spl_set_id": ["71873567-9594-452a-bb92-34a129adecac"], "pharm_class_epc": ["Sodium-Glucose Cotransporter 2 Inhibitor [EPC]", "Dipeptidyl Peptidase 4 Inhibitor [EPC]"], "pharm_class_moa": ["Sodium-Glucose Transporter 2 Inhibitors [MoA]", "Dipeptidyl Peptidase 4 Inhibitors [MoA]"], "manufacturer_name": ["Boehringer Ingelheim Pharmaceuticals, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "90 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0390-13)", "package_ndc": "0597-0390-13", "marketing_start_date": "20200423"}, {"sample": false, "description": "30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0390-71)", "package_ndc": "0597-0390-71", "marketing_start_date": "20200423"}], "brand_name": "Trijardy XR", "product_id": "0597-0390_ca86ce8b-9c04-47d8-94e3-ae041f251fab", "dosage_form": "TABLET, EXTENDED RELEASE", "pharm_class": ["Biguanide [EPC]", "Biguanides [CS]", "Dipeptidyl Peptidase 4 Inhibitor [EPC]", "Dipeptidyl Peptidase 4 Inhibitors [MoA]", "Sodium-Glucose Cotransporter 2 Inhibitor [EPC]", "Sodium-Glucose Transporter 2 Inhibitors [MoA]"], "product_ndc": "0597-0390", "generic_name": "empagliflozin, linagliptin, metformin hydrochloride", "labeler_name": "Boehringer Ingelheim Pharmaceuticals, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Trijardy XR", "active_ingredients": [{"name": "EMPAGLIFLOZIN", "strength": "25 mg/1"}, {"name": "LINAGLIPTIN", "strength": "5 mg/1"}, {"name": "METFORMIN HYDROCHLORIDE", "strength": "1000 mg/1"}], "application_number": "NDA212614", "marketing_category": "NDA", "marketing_start_date": "20200423", "listing_expiration_date": "20271231"}